Real-life treatment patterns and time to next treatment among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland Study
In the pre-PARPi era, prognosis for advanced OC was poor, particularly for patients with stage III tumours and visible residual disease or stage IV tumours regardless of the presence of residual disease. The increasing use of PARPis will hopefully help address the need for effective treatments in advanced OC.
Authors
- Annika Auranen (ORCID: https://orcid.org/0000-0002-9678-4684)
- B. Mascialino (ORCID: https://orcid.org/0000-0003-4154-4728)
- Outi Isomeri (ORCID: https://orcid.org/0009-0009-8460-8913)
- Nichola Roebuck
- Mikko Loukovaara (ORCID: https://orcid.org/0000-0002-4372-2367)
- Sari Käkelä
- J Idänpään-Heikkilä (ORCID: https://orcid.org/0000-0003-3762-5357)
- Mari Lahelma (ORCID: https://orcid.org/0000-0002-4845-0196)
- Heini Rauhamaa
- Sakari Hietanen (ORCID: https://orcid.org/0000-0003-4734-4743)
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- Public Health Institute (US)
- Glaxosmithkline (Finland) (FI)
- Tampere University Hospital (FI)
- GlaxoSmithKline (Italy) (IT)
- Tampere University (FI)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2024-10-16
- DOI
- https://doi.org/10.2340/1651-226x.2024.40325
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- AstraZeneca
- Tays
- Turun Yliopistollinen Keskussairaala